Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29656597 | 1.00 | OXTR (0.41) | OXTRHSD11B1 | |
| SCHEMBL746185 | 0.80 | OXTR (0.48) | OXTRHSD11B1 | |
| SCHEMBL23645444 | 0.79 | OXTR (0.35) | OXTR | |
| SCHEMBL23668806 | 0.79 | OXTR (0.35) | OXTR | |
| SCHEMBL3923960 | 0.79 | OXTR (0.49) | OXTRHSD11B1 | |
| SCHEMBL11122795 | 0.79 | OXTR (0.49) | OXTRHSD11B1 | |
| SCHEMBL24505981 | 0.77 | OXTR (0.48) | OXTRHSD11B1 | |
| SCHEMBL23686169 | 0.76 | NR1H2 (0.35) | HSD11B1 | |
| SCHEMBL23668834 | 0.76 | PDE7A (0.37) | — | |
| SCHEMBL23645062 | 0.76 | PDE7A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114630832-A | Pyrimido-cyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021093758-A1 | PYRIMIDO DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093758-A1 | PYRIMIDO DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | OXTR 4579/4885HSD11B1 2179/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | OXTR 4579/4885HSD11B1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.